세계의 급성 췌장염 시장 - 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 유통 채널별, 지역별 부문 예측(2025-2033년)

Acute Pancreatitis Market Summary

The global acute pancreatitis market size was estimated at USD 3.37 billion in 2024 and is projected to reach USD 5.60 billion by 2033, growing at a CAGR of 5.8% from 2025 to 2033. The market is largely driven by rising awareness of pancreatic health, an increasing prevalence of lifestyle-related disorders, and advances in diagnostic and therapeutic approaches.

Growing adoption of minimally invasive procedures, improved imaging technologies, and the development of novel enzyme replacement and anti-inflammatory treatments are further supporting market expansion. In addition, ongoing clinical research and enhanced healthcare infrastructure continue to strengthen growth prospects for acute pancreatitis management.

The global market for acute pancreatitis is consistently growing, driven by evolving healthcare practices, lifestyle changes, and technological advancements. The increasing prevalence of risk factors such as gallstones, excessive alcohol intake, obesity, and metabolic disorders has contributed to a rising incidence of acute pancreatitis (AP), a serious inflammatory condition of the pancreas. Globally, AP affects approximately 30-40 individuals per 100,000 population annually, according to the National Library of Medicine, and is a major cause of gastrointestinal hospitalizations in the U.S. These dynamics are fueling demand for advanced diagnostic tools and therapeuticinterventions. Cutting-edge imaging technologies, including endoscopic ultrasound (EUS), CT scans, and MRI, enhance early diagnosis and treatment precision, while minimally invasive procedures and enzyme replacement therapies improve recovery outcomes and shorten hospital stays.

Global Acute Pancreatitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global acute pancreatitis market report based on drug class, distribution channel, and region.

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Analgesics
• Antibiotics
• Enzyme Inhibitors
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • Italy
  • UK
  • Spain
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
  • RoAPAC
• Latin America
  • Argentina
  • Brazil
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Global Acute Pancreatitis Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Global Acute Pancreatitis Market: Drug Class Estimates & Trend Analysis

• 4.1. Drug Class Market Share, 2024 & 2033
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
• 4.4. Analgesic
  • 4.4.1. Analgesic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Antibiotics
  • 4.5.1. Antibiotics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Enzyme Inhibitors
  • 4.6.1. Enzyme Inhibitors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Global Acute Pancreatitis Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2033
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Hospital Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Retail Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Online Pharmacies
  • 5.6.1. Online Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Global Acute Pancreatitis Market: Regional Business Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 6.4. North America
  • 6.4.1. North America Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1 Key Country Dynamics
    • 6.4.2.2 Type Disease Prevalence
    • 6.4.2.3 Regulatory Framework
    • 6.4.2.4 Reimbursement Framework
    • 6.4.2.5 U.S. Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1 Key Country Dynamics
    • 6.4.3.2 Type Disease Prevalence
    • 6.4.3.3 Regulatory Framework
    • 6.4.3.4 Reimbursement Framework
    • 6.4.3.5 Canada Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1 Key Country Dynamics
    • 6.4.4.2 Type Disease Prevalence
    • 6.4.4.3 Regulatory Framework
    • 6.4.4.4 Reimbursement Framework
    • 6.4.4.5 Mexico Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Type Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Germany Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Type Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. France Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Type Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. Italy Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. UK
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Type Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. UK Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Type Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Type Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Norway Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Type Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Type Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. China Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Japan
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Type Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. Japan Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Type Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Type Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Type Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. Thailand Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. South Korea
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Type Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. South Korea Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.8. RoAPAC
    • 6.6.8.1. Key Country Dynamics
    • 6.6.8.2. Type Disease Prevalence
    • 6.6.8.3. Regulatory Framework
    • 6.6.8.4. Reimbursement Framework
    • 6.6.8.5. RoAPAC Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.7.2. Argentina
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Type Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Argentina Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Brazil
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Type Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. Brazil Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East & Africa
• 6.9. Middle East & Africa Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
• 6.10. Saudi Arabia
  • 6.10.1.1. Key Country Dynamics
  • 6.10.1.2. Type Disease Prevalence
  • 6.10.1.3. Regulatory Framework
  • 6.10.1.4. Reimbursement Framework
  • 6.10.1.5. Saudi Arabia Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.11. South Africa
  • 6.11.1.1. Key Country Dynamics
  • 6.11.1.2. Type Disease Prevalence
  • 6.11.1.3. Regulatory Framework
  • 6.11.1.4. Reimbursement Framework
  • 6.11.1.5. South Africa Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.12. Kuwait
  • 6.12.1.1. Key Country Dynamics
  • 6.12.1.2. Type Disease Prevalence
  • 6.12.1.3. Regulatory Framework
  • 6.12.1.4. Reimbursement Framework
  • 6.12.1.5. Kuwait Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. AbbVie Inc
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Amgen Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Baxter
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Bayer AG
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Boehringer Ingelheim International GmbH
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Lilly USA, LLC
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Fresenius SE & Co. KGaA
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Hikma Pharmaceuticals PLC
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Johnson & Johnson
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Merck & Co., Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Novartis AG
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. Sanofi
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Product Benchmarking
    • 7.5.12.4. Strategic Initiatives